Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ophthotech

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Novartis scores CHMP backing for cholesterol drug Leqvio

Potential first-in-class treatment moves closer to EU approval

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

Deal will expand production capacity for BNT162b2 candidate

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

Roche Basel Switzerland

Roche plans to launch rapid COVID-19 antigen test later this month

Swiss pharma also intends to file for emergency approval in the US

- PMLiVE

Novartis’ asciminib tops Pfizer’s Bosulif in chronic myeloid leukaemia trial

Drug improved major molecular response compared to existing med

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links